Late Breaking Abstract - Early response and remission with benralizumab in patients with severe asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP) in the prospective real-world ImPROve Asthma study

Source: International Congress 2022 – Late-breaking abstracts in airway disease

Session: Late-breaking abstracts in airway disease
Session type: Thematic Poster
Number: 4189

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Korn (Mainz, Germany), H. Watz (Grosshansdorf, Germany), B. Emmanuel (Gaithersburg, United States), T. Plate (Hamburg, Germany), M. Saathoff (Gießen, Germany), A. Shavit (Cambridge, United Kingdom), T. Grund (Hamburg, Germany), M. Lommatzsch (Rostock, Germany). Late Breaking Abstract - Early response and remission with benralizumab in patients with severe asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP) in the prospective real-world ImPROve Asthma study. 4189

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

• Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
• Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
• Respiratory sequelae of preterm birth across the life span